Paper35840720
Association of artificial intelligence-powered and manual quantification of programmed death-ligand 1 (PD-L1) expression with outcomes in patients treated with nivolumab ± ipilimumab.
Baxi V and 17 others. Mod Pathol, 2022. Cited by 52 papers, by iCite.
Cite this record
ConductScience Library. Association of artificial intelligence-powered and manual quantification of programmed death-ligand 1 (PD-L1) expression with outcomes in patients treated with nivolumab ± ipilimumab. Papers, record 35840720. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35840720
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Association of artificial intelligence-powered and manual quantification of programmed death-ligand 1 (PD-L1) expression with outcomes in patients treated with nivolumab ± ipilimumab.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Non-Small-Cell Lung | Major topic |
| Carcinoma, Transitional Cell | Major topic |
| Lung Neoplasms | Major topic |
| Urinary Bladder Neoplasms | Major topic |
| Humans | |
| B7-H1 Antigen | |
| Nivolumab | |
| Ipilimumab | |
| Artificial Intelligence | |
| Retrospective Studies | |
| Antibodies, Monoclonal | |
| Biomarkers, Tumor |
Source PubMed
References35
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30345906 | Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. | N Engl J Med | 2018 | https://conductscience.org/library/papers/30345906 | PubMed |
| 2 | 31656061 | Interobserver Reproducibility of PD-L1 Biomarker in Non-small Cell Lung Cancer: A Multi-Institutional Study by 27 Pathologists. | J Pathol Transl Med | 2019 | https://conductscience.org/library/papers/31656061 | PubMed |
| 3 | 26712084 | Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. | Lancet | 2016 | https://conductscience.org/library/papers/26712084 | PubMed |
| 4 | 26317305 | Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer. | Appl Immunohistochem Mol Morphol | 2015 | https://conductscience.org/library/papers/26317305 | PubMed |
| 5 | 28131785 | Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. | Lancet Oncol | 2017 | https://conductscience.org/library/papers/28131785 | PubMed |
| 6 | 31463730 | PD-L1 expression in gastric cancer determined by digital image analyses: pitfalls and correlation with pathologist interpretation. | Virchows Arch | 2020 | https://conductscience.org/library/papers/31463730 | PubMed |
| 7 | 28891423 | Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. | N Engl J Med | 2017 | https://conductscience.org/library/papers/28891423 | PubMed |
| 8 | 30478349 | Deep Semi Supervised Generative Learning for Automated Tumor Proportion Scoring on NSCLC Tissue Needle Biopsies. | Sci Rep | 2018 | https://conductscience.org/library/papers/30478349 | PubMed |
| 9 | 31399699 | Artificial intelligence in digital pathology - new tools for diagnosis and precision oncology. | Nat Rev Clin Oncol | 2019 | https://conductscience.org/library/papers/31399699 | PubMed |
| 10 | 26412456 | Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. | N Engl J Med | 2015 | https://conductscience.org/library/papers/26412456 | PubMed |
| 11 | 26994219 | Multispectral Imaging of T and B Cells in Murine Spleen and Tumor. | J Immunol | 2016 | https://conductscience.org/library/papers/26994219 | PubMed |
| 12 | 31060602 | Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy. | J Immunother Cancer | 2019 | https://conductscience.org/library/papers/31060602 | PubMed |
| 13 | 24872352 | Fully non-parametric receiver operating characteristic curve estimation for random-effects meta-analysis. | Stat Methods Med Res | 2017 | https://conductscience.org/library/papers/24872352 | PubMed |
| 14 | 30470933 | Precision immunoprofiling by image analysis and artificial intelligence. | Virchows Arch | 2019 | https://conductscience.org/library/papers/30470933 | PubMed |
| 15 | 30955977 | Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. | Lancet | 2019 | https://conductscience.org/library/papers/30955977 | PubMed |
| 16 | 27718784 | Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. | N Engl J Med | 2016 | https://conductscience.org/library/papers/27718784 | PubMed |
| 17 | 32300181 | Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer. | Mod Pathol | 2020 | https://conductscience.org/library/papers/32300181 | PubMed |
| 18 | 28664936 | PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability. | Mod Pathol | 2017 | https://conductscience.org/library/papers/28664936 | PubMed |
| 19 | 28420726 | Intra- and Interobserver Reproducibility Assessment of PD-L1 Biomarker in Non-Small Cell Lung Cancer. | Clin Cancer Res | 2017 | https://conductscience.org/library/papers/28420726 | PubMed |
| 20 | 31562797 | Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. | N Engl J Med | 2019 | https://conductscience.org/library/papers/31562797 | PubMed |
Cited by32
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 52 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42606343 | Inter-Rater Agreement in PD-L1 (22C3) Expression Evaluation in Colon Cancer. | Appl Immunohistochem Mol Morphol | 2026 | https://conductscience.org/library/papers/42606343 | PubMed |
| 42443785 | Unlocking the prognostic power of pathomics in bladder cancer: a machine learning odyssey across multiple centers. | BMC Med Imaging | 2026 | https://conductscience.org/library/papers/42443785 | PubMed |
| 42279570 | Artificial Intelligence in Dermatopathology: An Update and Review of the Current Literature. | Diagnostics (Basel) | 2026 | https://conductscience.org/library/papers/42279570 | PubMed |
| 42147747 | Advancements in Image-Based Artificial Intelligence in the Diagnosis and Treatment of Head and Neck Squamous Cell Carcinoma: A Narrative Review. | Int J Gen Med | 2026 | https://conductscience.org/library/papers/42147747 | PubMed |
| 41976406 | Integrating Artificial Intelligence into Breast Cancer Histopathology: Toward Improved Diagnosis and Prognosis. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/41976406 | PubMed |
| 41961172 | Medical biotechnology and artificial intelligence powered companion diagnostics: indispensable pillars driving next generation precision health care. | Biotechnol Lett | 2026 | https://conductscience.org/library/papers/41961172 | PubMed |
| 41867453 | Artificial Intelligence for Predicting Immunotherapy Efficacy in Non-Small Cell Lung Cancer. | J Inflamm Res | 2026 | https://conductscience.org/library/papers/41867453 | PubMed |
| 41754942 | Artificial Intelligence in Lung Cancer: A Narrative Review of Recent Advances in Diagnosis, Biomarker Discovery, and Drug Development. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/41754942 | PubMed |
| 41631127 | Applications and challenges of utilizing digital pathology and AI-enabled workflows in clinical trials. | J Pathol Inform | 2026 | https://conductscience.org/library/papers/41631127 | PubMed |
| 41590351 | Machine Learning in Biomarker-Driven Precision Oncology: Automated Immunohistochemistry Scoring and Emerging Directions in Genitourinary Cancers. | Curr Oncol | 2026 | https://conductscience.org/library/papers/41590351 | PubMed |
| 41340634 | Predicability of PD-L1 expression in cancer cells based solely on H&E-stained sections. | J Pathol Inform | 2025 | https://conductscience.org/library/papers/41340634 | PubMed |
| 41316486 | The role of artificial intelligence-based foundation models and "copilots" in cancer pathology: potential and challenges. | J Exp Clin Cancer Res | 2025 | https://conductscience.org/library/papers/41316486 | PubMed |
| 40968169 | Enhanced patient selection with quantitative continuous scoring of PD-L1 expression for IO treatment in metastatic NSCLC. | NPJ Precis Oncol | 2025 | https://conductscience.org/library/papers/40968169 | PubMed |
| 40867268 | Immune Biomarkers for Checkpoint Blockade in Solid Tumors: Transitioning from Tissue to Peripheral Blood Monitoring and Future Integrated Strategies. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40867268 | PubMed |
| 40750675 | Synergistic H&E and IHC image analysis by AI predicts cancer biomarkers and survival outcomes in colorectal and breast cancer. | Commun Med (Lond) | 2025 | https://conductscience.org/library/papers/40750675 | PubMed |
| 40305346 | Optimizing Immunotherapy: The Synergy of Immune Checkpoint Inhibitors with Artificial Intelligence in Melanoma Treatment. | Biomolecules | 2025 | https://conductscience.org/library/papers/40305346 | PubMed |
| 40243442 | Double-Multiplex Immunostainings for Immune Profiling of Invasive Breast Carcinoma: Emerging Novel Immune-Based Biomarkers. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40243442 | PubMed |
| 40189932 | PD-L1 Scoring Models for Non-Small Cell Lung Cancer in China: Current Status, AI-Assisted Solutions and Future Perspectives. | Thorac Cancer | 2025 | https://conductscience.org/library/papers/40189932 | PubMed |
| 40075729 | A Thorough Review of the Clinical Applications of Artificial Intelligence in Lung Cancer. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40075729 | PubMed |
| 39979258 | Predicting immunotherapy response of advanced bladder cancer through a meta-analysis of six independent cohorts. | Nat Commun | 2025 | https://conductscience.org/library/papers/39979258 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| PDCD1 | 5133 | PubTator's text mining | https://conductscience.org/library/genes/5133 | NCBI Gene |
| SRPRA | 6734 | PubTator's text mining | https://conductscience.org/library/genes/6734 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35840720
GET https://conductscience.org/api/papers/v1/35840720/references?page=2